• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indoles

5,7-Dibromo-1H-indole: A Promising Scaffold in Modern Medicinal Chemistry

5,7-Dibromo-1H-indole (CAS No. 36132-08-8) represents a critical intermediate in the development of bioactive compounds with diverse pharmacological applications. As a brominated indole derivative, this molecule exhibits unique structural features that enable it to interact with multiple biological targets. Recent studies have highlighted its potential in modulating inflammatory pathways, neurodegenerative disease progression, and cancer cell signaling, positioning it as a key player in the discovery of novel therapeutics. The strategic incorporation of bromine atoms at the 5 and 7 positions of the indole ring imparts distinct electronic properties, which are central to its biological activity and chemical reactivity.

5,7-Dibromo-1H-indole is structurally related to the indole core found in numerous natural products and pharmaceutical agents, such as serotonin and tryptophan derivatives. The bromination at the 5 and 7 positions introduces steric and electronic effects that significantly influence its binding affinity to target proteins. This structural modification has been shown to enhance the molecule's ability to inhibit specific kinases and modulate G protein-coupled receptors (GPCRs), making it a valuable scaffold for drug development. The synthesis of 5,7-Dibromo-1H-indole typically involves bromination reactions of indole derivatives, with recent advancements in catalytic methods improving its scalability and purity.

Recent research has focused on the pharmacological profiles of 5,7-Dibromo-1H-indole, particularly its role in targeting inflammatory mediators. A 2023 study published in Journal of Medicinal Chemistry demonstrated that this compound exhibits potent anti-inflammatory activity by suppressing the NF-κB signaling pathway. The bromine substituents are believed to modulate the molecule's interaction with toll-like receptors (TLRs), thereby reducing the production of pro-inflammatory cytokines such as TNF-α and IL-6. These findings suggest potential applications in the treatment of autoimmune disorders and chronic inflammatory conditions. Additionally, the compound's ability to inhibit COX-2 enzymes has been explored in the context of pain management and cancer therapy.

The biological activity of 5,7-Dibromo-1H-indole extends to neurodegenerative diseases, where it has shown promise in modulating protein misfolding and aggregation. A 2024 preclinical study in Neuropharmacology reported that this compound reduces amyloid-beta (Aβ) plaque formation in Alzheimer's disease models. The brominated indole scaffold appears to interfere with the aggregation process by stabilizing the native conformation of amyloidogenic proteins. This mechanism is distinct from traditional anti-amyloid therapies, offering a novel approach to neurodegeneration. Furthermore, the compound has been evaluated for its neuroprotective effects in Parkinson's disease models, where it demonstrated the ability to reduce dopaminergic neuron loss.

In the realm of oncology, 5,7-Dibromo-1H-indole has been investigated for its potential to target cancer cell proliferation pathways. A 2023 study in Cancer Research revealed that this compound selectively inhibits the PI3K/AKT/mTOR signaling axis in several cancer cell lines, including breast and pancreatic tumors. The bromine substituents are thought to enhance the molecule's ability to bind to phosphoinositide 3-kinase (PI3K) enzymes, thereby disrupting downstream signaling that promotes cell survival and metastasis. These findings underscore the compound's potential as a candidate for targeted cancer therapies, particularly in combination with existing chemotherapeutic agents.

The chemical synthesis of 5,7-Dibromo-1H-indole has been optimized through recent advances in asymmetric catalysis and green chemistry. A 2022 study in Organic Letters described a novel bromination protocol using transition metal catalysts to achieve high regioselectivity in the bromination of indole derivatives. This method reduces the formation of byproducts and minimizes the use of hazardous reagents, aligning with the principles of sustainable drug development. The scalability of this synthesis has enabled the production of 5,7-Dibromo-1H-indole in sufficient quantities for preclinical studies, which is critical for advancing its therapeutic potential.

Structural analogs of 5,7-Dibromo-1H-indole have also been explored for their pharmacological properties. A 2023 comparative study in Drug Discovery Today evaluated the effects of varying bromine positions and substituents on biological activity. The results indicated that the 5,7-dibrominated form exhibits superior potency compared to mono-brominated derivatives, particularly in modulating GPCRs and inhibiting kinases. These findings highlight the importance of precise functional group placement in optimizing the therapeutic efficacy of indole-based compounds. The structural versatility of 5,7-Dibromo-1H-indole also allows for the design of prodrugs and derivatives with enhanced bioavailability and reduced toxicity.

Despite its promising pharmacological profiles, the development of 5,7-Dibromo-1H-indole as a therapeutic agent faces challenges related to its metabolic stability and selectivity. A 2024 study in Drug Metabolism and Disposition investigated the in vivo metabolism of this compound in mice, revealing that it undergoes rapid hepatic conjugation and renal excretion. These metabolic pathways may limit its systemic exposure, necessitating the design of modified derivatives with improved pharmacokinetic properties. Additionally, efforts are underway to enhance the compound's selectivity for specific targets, reducing off-target effects that could compromise its therapeutic safety profile.

The growing interest in 5,7-Dibromo-1H-indole reflects its significance as a versatile scaffold in medicinal chemistry. Its ability to modulate multiple biological pathways, combined with the flexibility of its chemical structure, positions it as a valuable tool for the discovery of novel therapeutics. Ongoing research continues to uncover new applications and mechanisms of action for this compound, further solidifying its role in the development of innovative treatments for inflammatory, neurodegenerative, and oncological diseases.

• 51417-51-7(7-Bromo-1H-indole)
• 16567-18-3(8-Bromoquinoline)
• 74076-58-7(1H-Indole,3,4,6-tribromo-)
• 55119-10-3(1,3,6-tribromo-9H-carbazole)
• 105908-73-4(9H-Carbazole, 1,3-dibromo-)
• 16807-11-7(1-Bromo-9H-carbazole)
• 55119-09-0(1,3,6,8-Tetrabromocarbazole)
• 650583-75-8(6,8-Dibromo-quinoline)
• 4357-61-3(Acridine, 4-bromo-)
• 126811-31-2(4,7-Dibromo-1H-indole)